Quantcast
Last updated on April 16, 2014 at 13:39 EDT

Latest Biologic Stories

2014-03-31 08:28:42

-- Conference Call Today, March 31, 2014, at 10:00 a.m. (EDT) -- ROCKVILLE, Md., March 31, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, today reported financial results for the year ended December 31, 2013 and provided operational highlights. http://photos.prnewswire.com/prnvar/20130522/MM19465LOGO Recent Operational Highlights...

2014-03-28 08:26:35

MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, March 28, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission (EC) has approved Roche's new subcutaneous (SC) formulation of MabThera(®)( )(rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. Following the approval of Herceptin SC in...

2014-03-28 04:21:52

CAMBRIDGE, England, March 28, 2014 /PRNewswire/ -- Crescendo Biologics Limited (Crescendo) today announces it has been awarded the prize for Business Innovation at the Cambridge News Business Excellence Awards 2014. During 2013, Crescendo announced the Crescendo Mouse, a breakthrough in antibody fragment technology which allows the efficient generation of high-quality fully human single domain antibody VH fragments from a transgenic mouse. The Company also raised...

2014-03-27 12:30:38

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/rwdz5w/therapy_class ) has announced the addition of the "Therapy Class Overview: Rituximab biosimilar" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade,...

2014-03-27 12:29:39

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5sfksl/therapeutic_class ) has announced the addition of the "Therapeutic Class Overview: Psoriasis - Plaque Psoriasis & Psoriatic Arthritis - Novel Oral Drugs And Biologics To Change Future Treatment Paradigm" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and...

2014-03-27 08:34:12

Cannabinoid Receptor 1 is most recent GPCR to be targeted by RuiYi's iCAPS platform LA JOLLA, Calif. and SHANGHAI, March 27, 2014 /PRNewswire/ -- RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA. RuiYi has a pipeline of...

2014-03-27 08:33:57

DUBLIN, Mar. 27, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/x6dsmh/therapeutic_class) has announced the addition of the "Therapeutic Class Overview : Emergence of Biogenerics Era In Japan - It's Time to Welcome Antibody Biosimilars of Foreign Origins Soon" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) With three products and eight players already in market - Japan biosimilar market will enter new phase...

2014-03-25 23:04:58

Global regulators, industry professionals and academia will gather at the event in Miami, Florida from May 14 to 15 to discuss the current regulatory landscape, future research and drug development in Latin America. Washington, DC (PRWEB) March 25, 2014 Twelve regulatory authorities from around the world will be among attendees discussing the opportunities provided by collaborating to achieve harmonization in regulation at the Latin American Regulatory Conference (LARC) 2014. Global...

2014-03-25 23:04:25

Experts in industry, research and pharma will discuss complex drug market and regulation. Horsham, Pa. (PRWEB) March 25, 2014 Leaders in biosimilar innovation will provide an in-depth, comparative analysis of the current global debates and trends in biosimilar regulation at the DIA 2014 50th Annual Meeting, from June 15 to 19 at the San Diego Convention Center. The “Trends in Biosimilars Regulation Within Developed and Emerging Markets” session will be held on June 19 at 10:45 a.m....

2014-03-24 23:03:12

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that based on compelling data generated by the SMARTag™ ADC platform, it has increased its minority investment in Redwood Bioscience. The proprietary SMARTag precision protein-chemical engineering platform and novel toxin-linker technologies developed by Redwood enable the generation of homogeneous...